Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Talk topics
- The kinetochore
- Molecular composition of the human kinetochore
- Kinetochore proteins assemble in a temporal order
- CENP-F localization at different stages of G2
- Defining temporal orders of assembly
- FRAP studies and kinetochore
- Turnover dynamics of kinetochore proteins
- What is the kinetochore?
- CENP-E: a kinesin like motor
- CENP-E exhibits a dynamic localization pattern
- CENP-E is essential for microtubule attachment
- The HEC1/Ndc80 complex
- Different phenotypes for various depletions
- Three steps of the mitotic checkpoint pathway
- Checkpoint proteins localize to kinetochores
- The kinetochore and its relation to cancer
- The mitotic checkpoint and cancer
- Mitotic checkpoint genes are essential
- Mitotic checkpoints and genome instability
- The kinetochore as a mitosis specific target
- Inhibitors of mitosis
- Ansamycins are inhibitors of Hsp90
- 17-AAG blocks assembly of CENP-H and I
- Histone deacetylase inhibitors
- HDI delays human tumor cell lines in mitosis
- HDI interferes protein assembly onto kinetochore
- Not all kinetochore localized proteins are affected
- The depletion is not a result of degradation
- FTI's block farnesylation of proteins
- FTI-2153 alters the localization of CENP-F
- Effect of FTI on lung cancer cells
- Inhibitors of kinetochore/spindle proteins
- Kinase inhibitors-Aurora and Plk1
- Polo kinases - Plk1-4
- Pros and cons of targeting the mitotic checkpoint
- Linking chromosome missegregation to cell death
- The checkpoint and apoptosis pathways
- Hela cells depleted of hNuf2 accumulate in mitosis
- Timelapse videos of mitotically arrested cells
- Hela cells blocked in mitosis undergo apoptosis
- Patient response
- Conclusions and future directions
Topics Covered
- Mitosis is critical for cells to proliferate and is a major target of current anti-cancer drugs such as paclitaxel and vinca alkaloids
- Characterization of proteins essential for mitosis has made available the opportunity to develop new anti-mitotic agents
- Expanding the number of anti-cancer drug targets should significantly improve the response of tumors to chemotherapies
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Yen, T. (2009, May 3). The kinetochore as a target for the development of mitosis specific anti-cancer drugs [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 22, 2024, from https://doi.org/10.69645/TXHU7407.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Tim Yen has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Hide